Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, has entered into an agreement with Exeltis (“Exeltis”) (a division of the global pharmaceutical group Insud Pharma) to develop, manufacture and commercialize a novel preclinical candidate from Aptorum in the following territories: the European Union and Latin America (with an option to expand the collaboration to the United States). This novel candidate is intended to target woman’s health and gynecological conditions, such as endometriosis or related conditions. Under the Agreement, Aptorum Group will retain the development rights in other jurisdictions in the world, as well as the right to develop the novel candidate into a drug product. Commercialisation of the product is subject to relevant regulatory approvals in their respective jurisdictions.
Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented: “Endometriosis is a systemic gynecological condition that is often painful and chronic, estimated to affect approximately 10% of reproductive-age women1. Symptoms of endometriosis include, but are not limited to chronic pain and in extreme cases infertility, thereby placing significant physical, emotional and economical impact on the patients. Currently, the mainstay of treatment includes surgery and/or hormonal treatment with oral contraceptives, neither of which are ideal, especially for reproductive aged women suffering such disease2. We believe that the candidate’s non-hormonal approach has the potential to address such unmet needs and we are excited to partner with Exeltis to develop this product to provide patients with a viable alternative.”
Exeltis is a fast-growing division of the integrated health sciences group Insud Pharma. It boasts a leadership position in the Women's Health segment, and is constantly innovating and seeking new treatments and devices to improve women's health and wellbeing around the world. With a global footprint spanning over 40 countries, Exeltis has a team of more than 4,000 professionals supported by a global manufacturing network. Exeltis' overarching goal is to support and care for women throughout every stage of life. It offers an extensive portfolio of products to respond to women's needs in the areas of fertility, reproductive health, contraception, pregnancy, childbirth and menopause. In recent years, Exeltis has also diversified into Central Nervous System (CNS), Ophthalmology and Endocrinology.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology and Research.
For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020.
As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.
This press release is provided “as is” without any representation or warranty of any kind.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Aptorum Group Limited
Investor Relations Department:
+44 20 80929299
Redchip – Financial Communications United States
+1 407 491 4498
Actifin – Financial Communications Europe
+33 1 56 88 11 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Luminary Launches New Subscription Channel on Apple Podcasts15.6.2021 22:27:00 EEST | Press release
Luminary, a subscription podcast network, today launched a new channel on Apple Podcasts, making all Luminary Original podcasts available globally to Apple Podcasts listeners in more than 170 countries. “We’re thrilled to collaborate with Apple, the house that built podcasting, to bring our original content to millions of listeners across the world,” said Simon Sutton, Luminary CEO. “When we founded Luminary, we believed that supporting premium subscription podcast content was important to listeners and creators alike. Distributing our content on Apple Podcasts is a critical step in fulfilling our vision,” said Matt Sacks, Luminary Co-founder and Executive Chairman. The Luminary channel includes more than 30 Luminary Original podcasts including Under the Skin with Russell Brand, Snap Judgment Presents: Spooked, The C-Word with Lena Dunham, and Leon Neyfakh’s Fiasco. The Luminary channel also includes access to The Midnight Miracle, a new show from creators Talib Kweli, yasiin bey, and
Pony.ai Becomes First Company to Test Driverless Vehicles on Public Roads in Both the U.S. and China15.6.2021 22:00:00 EEST | Press release
Silicon Valley-based Pony.ai, a leading autonomous driving company, today announced that it has begun regular and daily fully driverless testing on public roads in Fremont and Milpitas, CA. Along with the recent launch of fully driverless testing in Guangzhou, China, the company has become the first to get fully driverless automated vehicles on public roads in three cities across the world's two most dynamic mobility markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005458/en/ The successful kick-off is authorized by the previously announced driverless permit received from the California Department of Motor Vehicles for a fleet of six driverless vehicles, facilitating the total operational coverage over 100 square kilometers. Countless stealth technology iterations and numerous driverless readiness evaluations executed by a top-notch team have reinforced this significant milestone. As U.S. cities reopen in phases
Proteintech Group Celebrates 20-Year Anniversary15.6.2021 18:09:00 EEST | Press release
Proteintech Group, a leading manufacturer of antibodies and related products, is celebrating the 20th anniversary of its founding. To celebrate the achievements and challenges of the past years, Proteintech will host special events throughout the year with its customers, collaborators, and employees while still looking forward to future opportunities. “Over the years we have witnessed countless discoveries and we couldn’t be prouder of everything our customers have achieved. We want to thank all of our customer for their tireless efforts and sacrifices to advance scientific discovery,” Dr. Jason Li, CEO Proteintech Group was founded in early 2001 by a small group of scientists including its current CEO, Dr. Jason Li. The founders set out with a vision to produce an antibody for every single protein coded in the human genome. Comprehensive coverage of all human gene products is a massive undertaking, but critical because it is difficult for researchers to predict which targets may be re
Norsk Titanium Expands into the Industrial Application Market in Collaboration with Hittech Group15.6.2021 18:00:00 EEST | Press release
Norsk Titanium AS (Norsk Titanium; Euronext: NTI), a global leader in additive manufacturing of aerospace-grade titanium components, announced an expansion of its customer base into the industrial application market sector in collaboration with the Hittech Group, based in Den Haag, Netherlands. The production of the first industrial component in this development supports a Hittech end customer in the growing semiconductor equipment market. Norsk expects significant near-term investment by manufacturers in the semiconductor market as they seek to modernize their supply chains. This effort represents Norsk’s first step to support these modernization efforts with a faster, more cost efficient and environmentally friendly approach. Using Norsk’s revolutionary Rapid Plasma Deposition™ (RPD™) process, Norsk engineers have designed a titanium alloy preform that will reduce Hittech’s raw material needs by over 45 percent as compared to legacy wrought product used to fabricate the end component
i2c Becomes First Company to be a Visa Fintech Fast Track Member in Four Regions15.6.2021 17:15:00 EEST | Press release
i2c, a leading provider of digital payment and banking technology, today announced the extension of its membership in Visa’s Fintech Fast Track program to the Asia-Pacific region (AP), making it the first company to become an enablement partner in all four regions of the acclaimed program. As an enablement partner, i2c helps lay the foundation for fintechs to build and expand their products locally, regionally or globally over its single stack, modular platform. Designed to accelerate the process of integrating with Visa, the Fintech Fast Track program brings together services and expertise to support fintech companies in their efforts to launch payments solutions. Partners leverage the payment network’s reach, capabilities, and security to realize faster onboarding times, and allow fintechs to scale more quickly. “We are excited to be able to simplify the process of launching a card program in 10 more countries, as an extension of our commitment to being a truly global partner for our
Viking Malt: Foundation Stone Laid: Construction of the New Production Plant in Lahti, Finland, is Progressing as Planned15.6.2021 17:04:00 EEST | Press release
Viking Malt has laid the foundation stone for its new production plant in Lahti. The plan is that the new malting house will start its operations in 2023. It is about 90 million euro project in size and the production capacity will be ca. 85 000 tons per year. Owner Pär-Gustaf Relander and CEO Kasper Madsen hosted the ceremony at the construction site on Pippo-Kujala industrial area. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005825/en/ The time capsule and the representants from Construction Consultant Afry, Viking Malt and the Mayor of Lahti, Pekka Timonen. Photo by Viking Malt. The company is already over 130 years old and the key to success has always been to focus on high quality and to be open to innovation and new technology. The new plant is a continuation of this tradition. Building a new plant gives a unique opportunity to utilize the newest technology to both increase efficiency and to become more enviro
New Data Shows $30 Billion Streaming Advertising Disconnect Among Publishers, Brands and Consumers15.6.2021 17:00:00 EEST | Press release
Conviva, the intelligence cloud for streaming media, released its inaugural State of Streaming Advertising report today, revealing big gaps in how publishers, buyers and consumers perceive streaming ads, and what this means for the future of the multibillion dollar streaming ad industry. For example, while 69% of sellers believe ad quality on streaming is as good as on linear television, just over half of buyers feel similarly (55%) and only about a third of consumers agree (35%). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210615005329/en/ Conviva's State of Streaming Advertising 2021 (Graphic: Business Wire) “With streaming, there is an opportunity to provide high-quality creative to consumers, but we need to evaluate how and when we reach them,” said Scott McDonald, President & CEO, Advertising Research Foundation (ARF). “It’s time to move on from 1:1 targeting, with growing concerns over privacy and the challenge of s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom